CIRCASSIA LIMITED is a healthcare startup founded in 2006. Their core focus is on asthma management and diagnostics. The company is globally recognized for its NIOX® products, which are considered market leaders and leveraged by physicians to improve asthma diagnosis and management. Their commitment to providing exceptional customer service and after-sales support sets them apart in the industry.
The company's Series D investment saw a remarkable $98.00M infusion on April 19, 2011, with participation from noteworthy investors including Invesco and Imperial Innovations. This support aids Circassia Limited in advancing their mission to enhance the quality of life for millions of asthma patients by offering unparalleled support to healthcare professionals. Their dedication to developing the next generation of NIOX® innovations showcases their commitment to continuous improvement and innovation in the healthcare industry.
With an established track record of success and significant support from renowned investors, Circassia Limited continues to be at the forefront of revolutionizing asthma diagnostics and management, positioning itself as a promising venture for potential investment opportunities.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series D | $98.00M | 2 |
|
19 Apr 2011 |
| Series C | £15.25M | 3 |
|
14 Dec 2009 |
| Series B | £11.00M | 4 |
|
29 Jan 2008 |
| Series A | £6.00M | - | 01 Jan 2007 |
No recent news or press coverage available for CIRCASSIA LIMITED.
We care about your data, and we'd love to use cookies make your experience better.
